Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)
Sanofi's Paul Hudson scores an FDA OK for a rare disease drug — after a lengthy R&D odyssey
Right on the heels of an EMA recommendation for EU approval, Sanofi has scooped up the FDA’s OK for the first approved therapy to treat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
